Pleural
CDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma
Journal of Experimental & Clinical Cancer Research 2025 August 28 [Link] Federica Torricelli, Benedetta Donati, Veronica Manicardi, Mila Gugnoni, Francesca Reggiani, Gloria Manzotti, Pierluigi Di Chiaro, Cristian Ascione, Simonetta Piana, Riccardo Valli, Roberto Piro, Massimiliano Paci, Nicola Facciolongo, Filippo Lococo, Alessia Ciarrocchi Abstract Introduction: Diffuse Pleural Mesothelioma (DPM) is a rare and incurable cancer. Immune…
Read MoreIdentification of Cembrane Diterpenoids from Sinularia sp. That Reduce the Viability of Diffuse Pleural Mesothelioma Cell Lines
Journal of Natural Products 2025 August 25 [Link] Maria Orfanoudaki, Anam F Shaikh, Dongdong Wang, Vivek Singh, Lin Du, Jennifer A Wilson, Antony Wamiru, Ekaterina I Goncharova, Nathanael Pruett, Chuong D Hoang, Brice A P Wilson, Barry R O’Keefe Abstract Diffuse pleural mesothelioma (DPM) is a rare but aggressive late-onset cancer. A high-throughput screen of…
Read MoreIdentification of Cembrane Diterpenoids from Sinularia sp. That Reduce the Viability of Diffuse Pleural Mesothelioma Cell Lines
Journal of Natural Products 2025 August 25 [Link] Maria Orfanoudaki, Anam F Shaikh, Dongdong Wang, Vivek Singh, Lin Du, Jennifer A Wilson, Antony Wamiru, Ekaterina I Goncharova, Nathanael Pruett, Chuong D Hoang, Brice A P Wilson, Barry R O’Keefe Abstract Diffuse pleural mesothelioma (DPM) is a rare but aggressive late-onset cancer. A high-throughput screen of…
Read MorePartial Response to Nivolumab and Ipilimumab in a Patient With Malignant Pleural Mesothelioma and Pre-Existing Myasthenia Gravis Without Severe Flares or Immune-Related Adverse Events: A Case Report
Respirology Case Reports 2025 August 19 [Link] Mariko Higa, Tomoya Kuda, Yuichiro Ohya, Hidenori Kawasaki Abstract Detailed clinical data on the combination immune checkpoint inhibitor (ICI) therapy in patients with myasthenia gravis (MG) remain limited. We report a case of malignant pleural mesothelioma with previously undiagnosed ocular MG. Owing to hepatic dysfunction, reduced doses of…
Read MorePrognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy
Immunotherapy 2025 August 20 [Link] Giulia Mazzaschi, Roberto Rosati, Simona D’Agnelli, Roberta Minari, Francesca Trentini, Prisca Tamarozzi, Martina Manini, Martina Zinelli Ronzoni, Alessandra Dodi, Letizia Gnetti, Lorena Bottarelli, Cinzia Azzoni, Gianmarco Martines, Monica Pluchino, Ilaria Toscani, Alessandro Leonetti, Fabiana Perrone, Paola Bordi, Giovanni Bocchialini, Luca Ampollini, Federico Quaini, Marcello Tiseo Abstract Aim: A translational multiscale…
Read MorePemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab
Lung Cancer 2025 September [Link] Sawana Ono, Hirokazu Taniguchi, Koji Kuroda, Teppei Hashimoto, Asuka Okada, Yasuhiro Goto, Hidenori Kitai, Yoichi Nakamura, Shinsuke Ogusu, Tetsunari Hase, Takayo Ota 10, Noriyuki Ebi, Makoto Furugen, Taishi Harada, Yoshiaki Kinoshita, Takaki Mizoguchi, Katsumi Nakatomi, Yoshifumi Soejima, Takahiro Yamada, Shinnosuke Takemoto, Hiroshi Mukae Abstract There is limited evidence regarding the…
Read MoreMolecular expression of glycosaminoglycans modifies the plasticity of biphasic mesothelioma in favor of tumor progression
Glycoconjugate Journal 2025 August 13 [Link] Camila Machado Baldavira, Aline Nery Qualiotto, Tabatha Gutierrez Prieto, Sandra de Morais Fernezlian, Aline Assato, Marcelo Balancin, Teresa Takagaki, Alexandre Ab’Saber, Ana Paula Pereira Velosa, Walcy Rosolia Teodoro, Vera Luiza Capelozzi Abstract The study aimed to verify whether the expression of glycosaminoglycans (GAGs) and proteoglycans (PGs) in the tumor…
Read MoreA Promising Prognostic Indicator for Pleural Mesothelioma: Pan-Immuno-Inflammation Value
Journal of Clinical Medicine 2025 August 4 [Link] Serkan Yaşar, Feride Yılmaz, Ömer Denizhan Tatar, Hasan Çağrı Yıldırım, Zafer Arık 1, Şuayib Yalçın, Mustafa Erman Abstract Background: Pleural mesothelioma (PM) is a type of cancer that is difficult to diagnose and treat. Patients may have vastly varying prognoses, and prognostic factors may help guide the…
Read MoreInhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma
Oncogenesis 2025 August 11 [Link] Yantang Lin, Christelle Dubey, Tereza Losmanova, Samuel Oevgü Yasmin, Jean-Louis Reymond, Ren-Wang Peng, Haibin Deng, Patrick Dorn, Thomas Michael Marti Abstract Pleural mesothelioma (PM) is an aggressive, asbestos-linked cancer with limited treatment options and a poor prognosis. Lactate dehydrogenase B (LDHB) converts lactate to pyruvate, and its silencing reduces mitochondrial…
Read MoreInhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma
Oncogenesis 2025 August 11 [Link] Yantang Lin, Christelle Dubey, Tereza Losmanova, Samuel Oevgü Yasmin, Jean-Louis Reymond, Ren-Wang Peng, Haibin Deng, Patrick Dorn, Thomas Michael Marti Abstract Pleural mesothelioma (PM) is an aggressive, asbestos-linked cancer with limited treatment options and a poor prognosis. Lactate dehydrogenase B (LDHB) converts lactate to pyruvate, and its silencing reduces mitochondrial…
Read More